Inactive Instrument

News Kazia Therapeutics Australian S.E.

Equities

KZA

AU000000KZA9

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS	05-01	PR
Kazia Therapeutics Limited Reports Successful Stage 1 Completion of the EVT801 Phase 1 Clinical Trial in Advanced Cancer Patients	05-01	CI
Kazia Therapeutics : Purchase Agreement - Form 6-K	04-19	PU
Kazia Therapeutics Limited announced that it expects to receive $15 million in funding from Alumni Capital LP	04-18	CI
Kazia Therapeutics : Corporate Presentation	04-11	PU
Kazia Therapeutics Limited Reports Earnings Results for the Half Year Ended December 31, 2023	03-27	CI
Kazia Therapeutics : Half Yearly Report - 31 December 2023 - Form 6-K	03-27	PU
Kazia Therapeutics licenses paxalisib to Sovargen for intractable seizures in rare central nervous system diseases	03-21	PR
Kazia Therapeutics Limited Enters into an Exclusive Licensing Agreement Withsovargen Co., Ltd	03-21	CI
Kazia Therapeutics : EVT801 Progress Update Presentation	03-19	PU
Stocks Making Waves: Insights into Key Developments and Potential VTAK, TBIO, OCEA, ONMD, KZIA	02-27	AQ
Kazia Therapeutics' Lead Drug Candidate Meets Goal of Early-Stage Study	02-21	MT
Kazia Therapeutics Limited Reports Early Conclusion of Clinical Trial After Reaching Primary Endpoint	02-21	CI
Diffuse Intrinsic Pontine Glioma Pipeline, FDA Approvals, Clinical Trials Developments, and Companies 2024 (Updated)	02-21	AQ
Certain Warrants of Kazia Therapeutics Limited are subject to a Lock-Up Agreement Ending on 4-FEB-2024.	02-03	CI
Certain Ordinary Shares of Kazia Therapeutics Limited are subject to a Lock-Up Agreement Ending on 4-FEB-2024.	02-03	CI
Certain American Depositary Shares of Kazia Therapeutics Limited are subject to a Lock-Up Agreement Ending on 4-FEB-2024.	02-03	CI
KAZIA CONTINUES BOARD RENEWAL WITH TWO NEW APPOINTMENTS	01-18	PR
Kazia Therapeutics Limited Announces Appointment of Board Members	01-18	CI
Kazia Therapeutics Limited Announces Resignation of Karen Krumeich as Chief Financial Officer	01-12	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Kazia Therapeutics Australian S.E.

Equities

KZA

AU000000KZA9

Summary

Filters